<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902887</url>
  </required_header>
  <id_info>
    <org_study_id>HJW1601</org_study_id>
    <nct_id>NCT02902887</nct_id>
  </id_info>
  <brief_title>Monitored Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</brief_title>
  <official_title>A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salus University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study presents an opportunity to understand a novel, previously unreported controlled&#xD;
      intermittent alternate occlusion (CIAO) therapy glasses, which may improve the control of&#xD;
      Intermittent exotropia (IXT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of the exodeviation assessment (scaled 1-5)</measure>
    <time_frame>3-month</time_frame>
    <description>Intermittent Exotropia Control Scale (1-5) 5 = Constant exotropia 4 = Exotropia &gt; 50% of the 30-second period before dissociation 3 = Exotropia &lt; 50% of the 30-second period before dissociation 2 = No exotropia unless dissociated, recovers in &gt; 5 seconds&#xD;
1 = No exotropia unless dissociated, recovers in 1-5 seconds 0 = No exotropia unless dissociated, recovers in &lt; 1 second (phoria)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intermittent Exotropia</condition>
  <arm_group>
    <arm_group_label>Monitored CIAO therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants wear 3-hour CIAO therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, just observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Controlled Intermittent Alternate Occlusion (CIAO ) glasses</intervention_name>
    <description>Monitored CIAO therapy glasses</description>
    <arm_group_label>Monitored CIAO therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The following criteria must be met for the patient to be enrolled in the study:&#xD;
&#xD;
          1. Age 3 to 11 years old&#xD;
&#xD;
          2. Intermittent exotropia (manifest deviation) meeting all of the following criteria:&#xD;
&#xD;
               -  Intermittent exotropia at distance OR constant exotropia at distance and either&#xD;
                  intermittent exotropia or exophoria at near&#xD;
&#xD;
               -  Exodeviation at least 10PD at distance OR 15PD at near measured by prism and&#xD;
                  alternate cover test (PACT)&#xD;
&#xD;
          3. No previous surgical or non-surgical treatment for IXT (other than refractive&#xD;
             correction)&#xD;
&#xD;
          4. Visual acuity in the worse eye 20/40 (0.3 logMAR) or better on ATS HOTV for ages 3 - 5&#xD;
             and 20/25 (0.1 logMAR) or better on ATS HOTV for ages 6 - 11&#xD;
&#xD;
          5. No hyperopia greater than +3.50 D spherical equivalent in either eye&#xD;
&#xD;
          6. No myopia greater than -6.00 D spherical equivalent in either eye&#xD;
&#xD;
          7. Patients must be wearing refractive correction (spectacles or contact lenses) for at&#xD;
             least one week if refractive error (based on cycloplegic refraction performed within 6&#xD;
             months) meets any of the following:&#xD;
&#xD;
               -  Myopia &gt; -0.50 D spherical equivalent in either eye&#xD;
&#xD;
               -  Anisometropia &gt; 1.00 D spherical equivalent&#xD;
&#xD;
               -  Astigmatism in either eye &gt; 2.00 D if ≤ 5 years old and &gt; 1.50 D if &gt; 5 years old&#xD;
&#xD;
             Refractive correction for patients meeting the above refractive error criteria must&#xD;
             meet the following guidelines:&#xD;
&#xD;
               -  Anisometropia spherical equivalent must be within 0.25D of the full anisometropic&#xD;
                  difference correction&#xD;
&#xD;
               -  Astigmatism cylinder must be within 0.25D of full correction and axis must be&#xD;
                  within 5 degrees of full correction.&#xD;
&#xD;
               -  For hyperopia, the spherical component can be reduced at investigator discretion&#xD;
                  provided the reduction is symmetrical. Prescribing any refractive correction to&#xD;
                  yield lenses that are more myopic than -0.50 D spherical equivalent (SE) is&#xD;
                  considered deliberate overminus and is not allowed at enrollment. However,&#xD;
                  prescribing no correction or prescribing less than the full cycloplegic hyperopic&#xD;
                  correction (i.e., prescribing reduced plus) is not considered the same as&#xD;
                  overminusing for this protocol and is allowed because most patients without IXT&#xD;
                  but with hyperopic SE refractions in this range would not typically be prescribed&#xD;
                  a refractive correction.&#xD;
&#xD;
               -  For myopia, the intent is to fully correct, but the spherical component can be&#xD;
                  undercorrected by investigator discretion provided the reduction is symmetrical&#xD;
                  and results in no more than -0.50 D SE residual (i.e., uncorrected) myopia.&#xD;
                  Prescribing a correction that yields more than 0.50 D more minus SE than the&#xD;
                  cycloplegic refraction SE is considered deliberate overminus and is not allowed&#xD;
                  at enrollment.&#xD;
&#xD;
             Note that the refractive correction guidelines and the requirement to wear refractive&#xD;
             correction for at least one week apply not only to patients who require refractive&#xD;
             correction under the above criteria but also to any other patient who is wearing&#xD;
             refractive correction.&#xD;
&#xD;
          8. No atropine use within the last week&#xD;
&#xD;
          9. Gestational age &gt; 34 weeks and birth weight &gt; 1500 grams&#xD;
&#xD;
         10. Patient and/or parent is willing to accept randomization to either observation or CIAO&#xD;
             therapy.&#xD;
&#xD;
         11. Parent has a phone (or access to phone) and is willing to be contacted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Only phoria at both distance and near&#xD;
&#xD;
          2. Prior non-surgical treatment for IXT other than refractive correction (e.g., vergence&#xD;
             therapy, occlusion, vision therapy/orthoptics, or deliberate over-minus with&#xD;
             spectacles more than 0.50D)&#xD;
&#xD;
          3. Previous amblyopia treatment other than refractive correction within 1 year&#xD;
&#xD;
          4. Vision therapy/orthoptics for any reason within the last year&#xD;
&#xD;
          5. Interocular visual acuity difference more than 0.2 logMAR (2 lines on ATS HOTV for&#xD;
             patients 3 to &lt; 7 years old or 10 letters on E-ETDRS for patients ≥ 7 years old)&#xD;
&#xD;
          6. Investigator planning to initiate amblyopia treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingyun Wang, PhD</last_name>
    <phone>215-780-1376</phone>
    <email>jwang@salus.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Salus University</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyun Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exotropia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

